DNA Medicine Institute Receives Qualifying Therapeutic Discovery Grant

Cambridge, MA, November 3, 2010 – The DNA Medicine Institute (DMI), a biomedical research organization dedicated to advancing patient care and alleviating human suffering through innovation, has been awarded a $222,999 grant under the U.S. government’s Qualifying Therapeutic Discovery Project (QTDP) Program. This funding will further the development of DMI’s Universal Blood Sensor — a handheld, all-in-one diagnostic device engineered to replace traditional hospital laboratory systems with real-time, on-demand testing.

The QTDP program, created through the Patient Protection and Affordable Care Act of 2010, supports breakthrough medical technologies that address areas of urgent unmet need, enable early detection and intervention, reduce healthcare costs, and advance the nation’s long-term competitiveness in biomedical science and innovation. Projects selected for funding demonstrate strong potential for creating high-quality U.S. jobs while significantly improving patient outcomes.

DMI’s Universal Blood Sensor is designed to deliver a complete health assessment from a single drop of blood — without large analyzers, phlebotomy, or specialized laboratory personnel. The platform enables detection of disease states across all major organ systems, including the heart, lungs, kidneys, blood, brain, infection, and cancer. Its rapid, point-of-care capabilities enable immediate clinical insight and timely intervention in any setting.

“This investment allows us to accelerate the delivery of critical health information to patients everywhere — regardless of location, infrastructure, or economic circumstance,” said Eugene Y. Chan, M.D., President and Chief Scientific Officer of the DNA Medicine Institute. “By shrinking the testing lab into a handheld device, we’re opening the door to universal access to care.”